Drs Roy M. Fleischmann and Joel M. Gelfand discuss addressing patient concerns with biosimilars and provide take-home messages to clinicians utilizing biosimilars.
A presentation from Maui Derm Live 2021 featured insights on new drugs and data in acne.
Mancini discusses his SPD 2024 lecture, emphasizing off-label treatments, surrogate diagnostic markers, simpler therapies, and the importance of empathy and education.
Sarkar spoke with Dermatology Times after the ReV conference to discuss her session on vitiligo stigma.
Boehringer Ingelheim’s Cyltezo is the first and only FDA-approved interchangeable biosimilar to adalimumab.
Eight JAK inhibitors are approved by the FDA to treat autoimmune, inflammatory, and allergic conditions.
Take a look at this overview of the top 5 considerations to show how CBP/β-catenin antagonists can be utilized for skin rejuvenation and anti-aging by enhancing Wnt/p300/β-catenin transcription.
Researchers found an association between ADHD and three inflammatory conditions—atopic dermatitis, otitis media, and herpes simplex infection.
Experts describe roflumilast patient selection for plaque psoriasis treatment.
Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.
The ACMS president and scientific program chair share opportunities to discover innovations in Mohs surgery during this weekend’s meeting.
The overgrowth of fungi could cause the immune system to stop fighting cancer, according to a study.
Andrew Alexis, MD, MPH, reviews the case of a 66-year-old woman who presented with depigmented patches and provides clinical insights on barriers typically encountered during the management of this condition.
Robin Siperstein, MD, FAAD, shares practical tips in cosmetic dermatology at the 2024 SDPA Annual Summer Dermatology Meeting.
Panelists share parting advice and key takeaways on the optimal management of atopic dermatitis within the treatment landscape.
Zakiya Pressley Rice, MD, took a deep dive into how atopic dermatitis severity and increased rates of grade school absenteeism affect patients with skin of color during a recent Masterclasses in Dermatology meeting.
Understanding the difference in biology and clinical presentations of cutaneous conditions in different skin types is critical for health care professionals to treat a diverse population.
Miller, Vice President, Immunodermatology Disease Area Leader, Johnson & Johnson, spoke with Dermatology Times about recently published data supporting JNJ-2113's potential in this indication.
Caleb Kovell, MD and Junqian Zhang, MD demonstrated how teaming up increases the likelihood for positive patient outcomes in Mohs cases on the genitalia and perianal region.
The study design emphasizes elevated endpoints, particularly joint health, ensuring that the most relevant outcomes are prioritized for patient care.
Experts in dermatology share closing thoughts on the management of plaque psoriasis.
In the final part of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, review 4 real-world clinical cases of BCC and the treatments they utilized.
Stefan Weiss, MD, MBA, explains next steps for the oral treatment after the completion of phase 1b enrollment.
As deucravacitinib surpasses its 1-year milestone since approval, clinicians continue to monitor its real-world performance among patients.
Sherrif F. Ibrahim, MD, PhD, and Vishal Patel, MD, FAAD, FACMS, provide initial impressions of the case and discuss the use of immune checkpoint inhibitors.
The trial showcased the continued efficacy of apremilast, with 2-year data on the forefront.
To address the increased rates of skin cancer while keeping unique patient needs top of mind, there is a pressing need to increase options for treatment.